CAR T-cells in pediatric ALL with extramedullary disease

0 Views

07/14/23

Acute lymphoblastic leukemia (ALL) patients with extramedullary disease have been excluded from CAR T-cell therapy clinical trials. Susana Rives, MD PhD, Sant Joan de Déu Hospital, Barcelona, Spain, discusses the clinical trial evaluating CAR T-cells in pediatric ALL with extramedullary disease. Results show no difference in the incidence of neurotoxicity and cytokine-release syndrome between patients with and without extramedullary disease. Additionally, the complete remission rate and outcomes were the same in the two cohorts. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.